Altimmune (NASDAQ:ALT) Receives "Buy" Rating from HC Wainwright

Altimmune (NASDAQ:ALT - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright's price target points to a potential upside of 107.15% from the stock's previous close.

Several other research analysts also recently commented on the company. Stifel Nicolaus began coverage on Altimmune in a report on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price objective on the stock. William Blair reiterated a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $20.83.

Altimmune Price Performance

NASDAQ ALT traded up $0.01 during trading hours on Tuesday, reaching $5.79. 2,035,007 shares of the stock traded hands, compared to its average volume of 2,993,014. The stock has a 50 day simple moving average of $6.33 and a two-hundred day simple moving average of $7.08. Altimmune has a 1 year low of $5.14 and a 1 year high of $11.16. The company has a market cap of $446.14 million, a price-to-earnings ratio of -3.74 and a beta of 0.87.

Remove Ads

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. On average, sell-side analysts forecast that Altimmune will post -1.35 EPS for the current fiscal year.

Insider Activity at Altimmune

In other Altimmune news, CFO Gregory L. Weaver purchased 10,000 shares of Altimmune stock in a transaction that occurred on Thursday, March 13th. The shares were bought at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.10% of the stock is owned by company insiders.

Institutional Trading of Altimmune

Several large investors have recently bought and sold shares of ALT. Ameriprise Financial Inc. boosted its position in Altimmune by 35.6% during the 4th quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock valued at $37,888,000 after acquiring an additional 1,378,854 shares in the last quarter. Bellevue Group AG boosted its position in Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company's stock valued at $5,303,000 after acquiring an additional 263,660 shares in the last quarter. Invesco Ltd. boosted its position in Altimmune by 679.2% during the 4th quarter. Invesco Ltd. now owns 247,086 shares of the company's stock valued at $1,781,000 after acquiring an additional 215,375 shares in the last quarter. Millennium Management LLC boosted its position in Altimmune by 139.8% during the 4th quarter. Millennium Management LLC now owns 345,637 shares of the company's stock valued at $2,492,000 after acquiring an additional 201,484 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in Altimmune by 33.2% during the 4th quarter. Two Sigma Investments LP now owns 605,303 shares of the company's stock valued at $4,364,000 after acquiring an additional 151,001 shares in the last quarter. 78.05% of the stock is owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.